Smith Lisa C, Bertolotti Page, Curran Kathleen, Jenkins Bonnie
Cancer Centers of the Carolinas, Greenville, SC, USA.
Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):37-52. doi: 10.1188/08.CJON.S1.37-51.
The novel immunomodulatory drugs lenalidomide and thalidomide and the novel proteasome inhibitor bortezomib can cause gastrointestinal side effects, including constipation, diarrhea, nausea, and vomiting, which can have a deleterious effect on quality of life and interfere with optimal therapy. The International Myeloma Foundation's Nurse Leadership Board developed this consensus statement for the management of gastrointestinal side effects associated with novel therapies to be used by healthcare providers in any medical setting. It includes grading criteria and general recommendations for assessing and managing the side effects. Although constipation, diarrhea, nausea, and vomiting are expected side effects associated with novel therapies for multiple myeloma, they are manageable with appropriate medical interventions.
新型免疫调节药物来那度胺和沙利度胺以及新型蛋白酶体抑制剂硼替佐米可引起胃肠道副作用，包括便秘、腹泻、恶心和呕吐，这些副作用会对生活质量产生有害影响并干扰最佳治疗。国际骨髓瘤基金会护士领导委员会制定了这份关于新型疗法相关胃肠道副作用管理的共识声明，供任何医疗环境中的医疗服务提供者使用。它包括评估和管理副作用的分级标准及一般建议。虽然便秘、腹泻、恶心和呕吐是多发性骨髓瘤新型疗法预期的副作用，但通过适当的医学干预是可以控制的。
